一个急性心肌梗塞病例发生在一个用阿纳格雷利德治疗的患有基本血小板血症的患者身上
Ekrem Yetiskul1, Aqsa Nisar1, Salman Khan1
1Department of Internal Medicine, Staten Island University Hospital, Staten Island, USA.
European journal of case reports in internal medicine
|March 8, 2024
概括
阿纳格利利德有效降低基本血小板血 (ET) 的血小板计数,但可能通过激活血小板增加血小板血风险. 密切监测患者是否出现心肌梗塞等副作用至关重要.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 基本血小板血 (ET) 是一种骨髓增殖性疾病,其特征是血小板数量升高.
- 患有ET的患者面临高血栓栓塞的风险,需要治疗以降低血小板水平.
- 阿纳格雷利德是一种常见的药物,用于管理ET中的血栓细胞形成.
研究的目的:
- 突出阿纳格利利德在治疗精性血小板血症中的双重作用.
- 为了强调阿纳格利利德尽管具有降血小板的能力,但其潜在的前血栓效应.
- 强调监测严重副作用的重要性,例如心肌梗塞.
主要方法:
- 病例报告介绍了一名ET患者的病例报告,该患者接受了阿纳格利利德和基尿素治疗.
- 综述阿纳格雷利德的作用机制,重点关注血小板的产生和激活.
- 对ET患者的阿纳格雷利德治疗的潜在风险和益处的分析.
主要成果:
- 阿纳格利利德有效地降低了ET患者的血小板计数.
- 阿纳格雷利德可能会增加血小板激活和反应性,可能导致前血栓状态.
- 病例报告详细介绍了一名患者在接受阿纳格利利德治疗期间经历了急性ST升高心肌梗塞.
结论:
- 阿纳格利利德在降低血小板数量的有效性伴随着增加血小板激活和血栓事件的风险.
- 对于接受安格雷利德治疗ET的患者来说,密切监测血栓事件的临床监测至关重要.
- 在处方阿纳格利利德时,需要采取均衡的方法,仔细权衡其治疗效益与严重副作用的风险,如心肌梗塞.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
512
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
512
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
01:16Antianginal Drugs: Nitrates and β-Blockers
586
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
586